SciSparc (SPRC) Real Estate - Gross (2016 - 2017)
SciSparc (SPRC) posted Real Estate - Gross of $31000.0 for Q3 2017, up 82.35% sequentially from $17000.0 in Q2 2017.
SciSparc (SPRC) Real Estate - Gross (2016 - 2017) Analysis & Trends
SciSparc has reported Real Estate - Gross for 2 years, with the latest figure at $31000.0 in Q3 2017.
- Quarterly Real Estate - Gross changed N/A year-over-year to $31000.0 in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $31000.0 (changed N/A YoY) and the FY2016 annual result came in at $11000.0, changed N/A from the prior year.
- Real Estate - Gross climbed to $31000.0 in Q3 2017 per SPRC's latest filing, from $17000.0 in the prior quarter.
- Over five years, Real Estate - Gross peaked at $31000.0 in Q3 2017 and troughed at $11000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | SciSparc | 831,418.60 | 831,418.60 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 31,000.00 |
| Jun 30, 2017 | 17,000.00 |
| Mar 31, 2017 | 11,000.00 |
| Dec 31, 2016 | 11,000.00 |